Anthropic buys one-person biotech to launch internal drug programs

Acquiring a one-person startup

Anthropic has officially acquired Mithril Medicine, a specialized biotech company that consists of only one employee. The startup focuses on developing treatments for two rare forms of muscular dystrophy. By bringing this company into its fold, Anthropic is signaling a serious move into the pharmaceutical industry.

The founder of Mithril Medicine, Cody Tranbarger, has joined Anthropic following the deal. While the specific financial terms of the acquisition were not disclosed, the move allows Anthropic to begin its own internal drug discovery programs. This transition follows Anthropic's recent Nasdaq IPO filing, which highlighted the potential for AI to discover new cures as a primary benefit.

Tranbarger previously operated Mithril Medicine as a solo venture, using the Claude AI model to manage the company's heavy lifting. He used the tool to organize complex contracts, logistics, and experiments across 11 different external laboratories. This success story serves as a proof of concept for how a single person can manage a biotech operation using AI.

Accelerating the lab pipeline

Anthropic reported that Mithril Medicine successfully moved a potential treatment from a basic idea to promising results in mice in less than 18 months. The research specifically targets LAMA2-related congenital muscular dystrophy. In a technical report, the company shared that mice treated with a specific antibody design showed about twice the grip strength of untreated mice.

The company is now looking to scale these efforts significantly. If the current candidates perform well in further testing, Anthropic estimates that a drug could enter human clinical trials as early as late 2028. This timeline represents a push to move from digital research to physical medicine in a relatively short window of time.

To support this growth, Anthropic has also launched Claude Science, a dedicated workbench designed specifically for researchers. The company previously announced that Claude had already designed working protein binders. These tools are intended to help scientists navigate the various bottlenecks that exist throughout the entire drug development process.

Results from six partners

Anthropic is also collaborating with six different organizations to test Claude's capabilities in diverse biotech applications. At Generate Biomedicines, scientists used Claude Code to redesign a CAR T-cell cancer therapy. The AI-assisted design was about 70% shorter than the standard version and allowed immune cells to make roughly 10 times as many receptors in lab tests.

Divergence Labs used Claude to work on a treatment for food allergies. The AI generated roughly 35,000 antibody designs in about one month, mostly on its own. Out of those, three tested designs were able to dislodge the allergy molecule IgE more effectively than the medication currently on the market.

Other partners reported significant efficiency gains in their specific workflows. BigHat Biosciences used Claude to propose changes to two antibody fragments, leading to variants that bound more than 10 times more tightly than the originals. These results demonstrate how AI can be used to rapidly iterate on complex biological designs that would normally take much longer to produce manually.

Streamlining clinical data

Beyond designing new molecules, Claude is being used to handle the massive amounts of documentation required in the pharmaceutical industry. Enveda connected its manufacturing records to Claude and tested the system on 1,061 pages of data. The AI caught all 11 issues found by human reviewers, plus seven additional issues that the humans had missed entirely.

This automation led to a massive increase in speed for Enveda's team. They reported that review time fell by 89%, dropping from almost 26 hours to just under three hours. Additionally, Claude drafted a portion of a clinical trial application in only four hours, a task that would have taken about three months to complete by hand.

Other major players are also integrating these tools into their long-term strategies. Bristol Myers Squibb is currently using Claude to assess trial plans and estimate success chances for an early-stage drug. They plan to expand this work in 2027. Meanwhile, The Column Group is setting up a new company called Pleiades to run its drug programs entirely using Claude.

The path to human trials

While the results from these partnerships are impressive, Anthropic emphasizes that the research is still in the early stages. Most of the drugs currently being discussed have not yet reached the stage of human testing. The company describes the current work as mostly preclinical, meaning it is still being tested in laboratory settings or on animals.

The goal for Anthropic is to scale these operations substantially to move toward clinical applications. By using AI to handle the